Robert H. Dumanois

Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.

Sheryl K Elkin, A. Tsimberidou, D. Pritchard, 2020, Clinical lung cancer.

Cancer patient management: Current use of next-generation sequencing in the EU TOP4.

J. L. Costa, G. Pruneri, Chiara Rolando, 2022, Journal of cancer policy.

Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.

S. Ramsey, J. Roth, J. Carlson, 2014, The oncologist.

The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer

M. Broder, P. Billings, E. Chang, 2015, International Journal of Clinical Oncology.